Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments

Clinical trials requiring the collection of pharmacokinetic information often specify blood samples to be taken at fixed times. This may be feasible when trial participants are in a controlled environment such as in early phase clinical trials, however it becomes problematic in trials where patients are in an out-patient clinic setting such as in late phase drug development. In such a situation it is common to take blood samples when it is convenient for all involved and may result in data that are uninformative. This paper proposes an approach to pharmacokinetic study design that allows greater flexibility as to when blood samples can be taken and still result in data that allows satisfactory parameter estimation. The sampling window approach proposed in this paper is based on determining time intervals around the D-optimum pharmacokinetic sampling times. These intervals are determined by allowing the sampling window design to result in a specified level of efficiency when compared to the fixed times D-optimum design. Several approaches are suggested for dealing with this design problem.

[1]  L Aarons,et al.  Population pharmacokinetics of tobramycin. , 1989, British journal of clinical pharmacology.

[2]  Lewis B. Sheiner,et al.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  J. Nedelman,et al.  Application of Sparse Sampling Approaches in Rodent Toxicokinetics: A Prospective View , 1994 .

[4]  Jon Wakefield,et al.  Statistical methods for population pharmacokinetic modelling , 1998, Statistical methods in medical research.

[5]  Stephen Duffull,et al.  Modeling and Simulation for Clinical Trial Design Involving a Categorical Response: A Phase II Case Study with Naratriptan , 2001, Pharmaceutical Research.

[6]  Jean-Marie Rocchisani,et al.  Comparison of ED, EID, and API Criteria for the Robust Optimization of Sampling Times in Pharmacokinetics , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[7]  France Mentré,et al.  Optimal Design of a Population Pharmacodynamic Experiment for Ivabradine , 2004, Pharmaceutical Research.

[8]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[9]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[10]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.

[11]  D Z D'Argenio,et al.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.

[12]  France Mentré,et al.  Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.

[13]  Luc Pronzato,et al.  Information matrices with random regressors. Application to experimental design , 2002 .

[14]  H. Chernoff Locally Optimal Designs for Estimating Parameters , 1953 .

[15]  James E. Bennett,et al.  The Bayesian modeling of covariates for population pharmacokinetic models , 1996 .

[16]  Stephen B. Duffull,et al.  Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  M. Rowland,et al.  Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies , 2004, European Journal of Clinical Pharmacology.

[18]  Mats O. Karlsson,et al.  Comparison of some practical sampling strategies for population pharmacokinetic studies , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[19]  P. Laycock,et al.  Optimum Experimental Designs , 1995 .

[20]  R Gomeni,et al.  Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  David Z. D'Argenio,et al.  Optimal sampling times for pharmacokinetic experiments , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[23]  France Mentré,et al.  Sparse-Sampling Optimal Designs in Pharmacokinetics and Toxicokinetics* , 1995 .